Giant Cell Arteritis

In adults aged 50 years or older with suspected GCA, immediately ask about transient or persistent monocular visual loss, diplopia, jaw claudication, scalp or tongue ischemia, and focal neurologic symptoms. Cranial GCA can cause sudden permanent visual loss and stroke, and the relevant cranial arterial territories include the temporal, ophthalmic, posterior ciliary, and vertebral arteries.BMJ+3BMJGiant cell arteritis - Symptoms, diagnosis and treatment | BMJ Best PracticeAHA JournalsLarge Vessel Vasculitis Revisited: Mechanistic Insights and ...NatureA new era for giant cell arteritis | EyeNatureGlobal epidemiology of vasculitis | Nature Reviews Rheumatology

Begin high-dose glucocorticoids once GCA is suspected; do not delay therapy for biopsy or imaging. Prompt steroid treatment can prevent further visual loss, although visual loss can occur at treatment initiation and during glucocorticoid tapering.Nature+2NatureGiant cell arteritis: reviewing the advancing diagnostics and management | EyeWiley2021 American College of Rheumatology/Vasculitis ...WileyDiagnosis and management of giant cell arteritis: Major ...

Escalate same day for ophthalmologic assessment when visual symptoms, diplopia, or suspected anterior ischemic optic neuropathy is present, and involve rheumatology urgently to coordinate disease confirmation and glucocorticoid-sparing therapy. Established ischemic events, including contralateral visual loss from anterior ischemic optic neuropathy, identify patients at higher subsequent risk of permanent visual loss.NatureNatureGiant cell arteritis: reviewing the advancing diagnostics and management | Eye

Obtain a confirmatory test in suspected GCA: temporal artery biopsy (TAB), temporal artery ultrasound, or both. A diagnosis based only on symptoms, examination, and inflammatory markers risks overdiagnosis because presenting symptoms may be nonspecific and inflammatory markers are not specific for GCA.Nature+1NaturePractice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines | EyeOxford AcademicBritish Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis _Free

For a cranial phenotype, perform vascular ultrasonography of the temporal and axillary arteries where expertise is available. EULAR-oriented practice places temporal and axillary ultrasound as first-line imaging; in a patient with high pretest probability, a noncompressible halo sign can replace TAB.BMJBMJPerformance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care Ultrasound is more sensitive but less specific than TAB, making pretest probability and image quality consequential when interpreting a positive result.NatureNaturePractice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines | Eye

Use TAB when ultrasound is unavailable, nondiagnostic, discordant with clinical probability, or when tissue confirmation will materially alter long-term immunosuppression decisions. TAB has pooled sensitivity of 61% and specificity of 98%; therefore, a positive result is highly confirmatory, but a negative result should prompt reassessment for imaging-supported cranial or extracranial disease rather than automatic discontinuation of treatment.WileyWileyGiant Cell Arteritis: A Systematic Review and Meta‐Analysis of ...

Do not apply the 2022 ACR/EULAR classification criteria as a stand-alone diagnostic rule. They were developed to classify research populations after medium- or large-vessel vasculitis has been identified; in a real-world suspected-GCA cohort, diagnostic use retained high sensitivity but had lower specificity, and patients without cranial manifestations could fail to meet criteria despite typical imaging abnormalities outside the scored vascular territories.BMJ+1BMJPerformance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical careScienceDirectAB0739 PERFORMANCE OF THE 2022 AMERICAN COLLEGE OF RHEUMATOLOGY/EULAR CLASSIFICATION CRITERIA FOR GIANT CELL ARTERITIS IN A COHORT OF PATIENTS WITH SUSPICION OF HAVING GIANT CELL ARTERITIS - ScienceDirect

Classify the presentation clinically as cranial GCA, extracranial large-vessel GCA, polymyalgia rheumatica-associated disease, or overlap. These phenotypes frequently overlap: cranial GCA is the most commonly diagnosed form, whereas extracranial disease generally involves the aorta and larger supra-aortic branches and may coexist with polymyalgic or constitutional symptoms.AHA Journals+1AHA JournalsLarge Vessel Vasculitis Revisited: Mechanistic Insights and ...NatureA new era for giant cell arteritis | Eye

A cranial-predominant syndrome is supported by new headache, abnormal temporal artery findings, jaw claudication, diplopia, or ischemic ocular symptoms; among these, jaw claudication, diplopia, and an abnormal temporal artery are particularly useful discriminators for positive vascular testing.BMJBMJGiant cell arteritis - Symptoms, diagnosis and treatment | BMJ Best Practice Occult cranial GCA can present without systemic symptoms, so absence of fever, weight loss, or polymyalgic symptoms should not lower concern enough to defer evaluation in a patient with ocular ischemia.NatureNaturePractice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines | Eye

A large-vessel-predominant syndrome should be considered with limb claudication, chest pain, back pain, or imaging evidence of aortic or branch-vessel inflammation. The clinically important downstream lesions are stenosis and aneurysm formation, including thoracic and abdominal aortic aneurysms; direct imaging is needed because cranial symptoms alone do not define the full vascular burden.Nature+1NatureA new era for giant cell arteritis | EyeWiley2021 American College of Rheumatology/Vasculitis ...

Before committing to prolonged treatment, actively reassess mimics when the clinical pattern, inflammatory markers, and imaging are discordant. In a suspected-GCA cohort, polymyalgia rheumatica and nonvasculitic ophthalmologic disorders accounted for substantial portions of patients meeting the 2022 classification score despite not having GCA, underscoring that a classification score cannot substitute for diagnostic adjudication.ScienceDirectScienceDirectAB0739 PERFORMANCE OF THE 2022 AMERICAN COLLEGE OF RHEUMATOLOGY/EULAR CLASSIFICATION CRITERIA FOR GIANT CELL ARTERITIS IN A COHORT OF PATIENTS WITH SUSPICION OF HAVING GIANT CELL ARTERITIS - ScienceDirect

High-dose glucocorticoids are the initial treatment once GCA is suspected. In a randomized trial, intravenous methylprednisolone given during the first 3 treatment days with oral prednisolone 40 mg/day was associated with faster glucocorticoid tapering, lower cumulative glucocorticoid exposure, and fewer relapses than placebo; patients with visual loss were excluded, so this trial does not establish intravenous treatment for acute visual ischemia.NatureNatureGiant cell arteritis: reviewing the advancing diagnostics and management | Eye

For long-term management, coordinate glucocorticoid tapering and relapse assessment with rheumatology. Targeted immunotherapy has changed GCA management, and current ACR guidance addresses glucocorticoid use and non-glucocorticoid immunosuppressive therapy, but regimen selection should account for ischemic phenotype, relapse history, cumulative steroid toxicity, and evidence of large-vessel disease.BMJ+2BMJBritish Society for Rheumatology guideline for diagnosis and treatment of giant cell arteritis | Practical NeurologyNatureGiant cell arteritis: reviewing the advancing diagnostics and management | EyeWiley2021 American College of Rheumatology/Vasculitis ...

Monitor clinically for recurrent headache, jaw claudication, visual symptoms, diplopia, limb claudication, chest pain, and back pain; recurrence of ischemic symptoms requires urgent reassessment rather than routine outpatient taper adjustment. Permanent visual loss after treatment has been reported at approximately 2.2% in one longitudinal study and 2.8% in pooled literature, with risk concentrated in those with prior ischemic events and potentially during steroid tapering.NatureNatureGiant cell arteritis: reviewing the advancing diagnostics and management | Eye

In patients with large-vessel involvement, use longitudinal vascular imaging to evaluate stenotic and aneurysmal complications. Imaging is central to recognizing aortic and major branch-vessel disease, which can remain clinically silent until complications such as limb ischemia, chest or back pain, or aneurysm are present.Nature+1NatureA new era for giant cell arteritis | EyeWiley2021 American College of Rheumatology/Vasculitis ...